Dazodalibep
Based on 1 Customer Validation
Dazodalibep (MEDI 4920) is a non-antibody fusion protein that acts as a CD40 ligand (CD40L) antagonist. Dazodalibep is used in the research of rheumatoid arthritis and Sjögren's syndrome.
For research use only. We do not sell to patients.
- Purity : 99.0%
- CAS No.: 2245953-10-8
- Molecular Weight:87.82 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Fusion - Alternative to antigen receptors (domain scaffold: TNC-F3, tenascin domain F3) 2 TNC-F3 domains
Species Reactivity
Human
In Vitro
Dazodalibep blocks the CD40-CD40L costimulatory interaction between T cells and CD40-expressing B cells and antigen-presenting cells[2].
Dazodalibep blocks costimulatory signal transduction between T cells, B cells, and antigen-presenting cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Target
TNFSF5/CD40L/CD154
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Alternative to antigen receptors (domain scaffold: TNC-F3, tenascin domain F3)2 TNC-F3 domains
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2245953-10-8
-
Appearance Liquid
-
Molecular Weight 87.82 kDa
-
Color Colorless to light yellow
-
SMILES
[Dazodalibep]
-
Synonyms
MEDI 4920; VIB 4920
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
Purity & Documentation
-
Data Sheet (267 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Dazodalibep
- 2245953-10-8
- MEDI 4920
- VIB 4920
- MEDI4920
- MEDI-4920
- VIB4920
- VIB 4920
- VIB-4920
- TNF Receptor
- rheumatoid arthritis
- B cell activation
- B cell proliferation
- CD40
- CD40-CD40L costimulatory interaction
- plasma cell differentiation
- T cell-dependent antibody production
- sj?gren's disease
- antigen-presenting cells
- T cells
- Inhibitor
- inhibitor
- inhibit